Lassa Virus: Can We Outsmart This Biothreat?
"Exploring innovative approaches to broaden our immune response and develop effective vaccines against Lassa fever."
In 2017, the global Coalition for Epidemic Preparedness (CEPI) identified Lassa virus disease as a top-priority biothreat, and in January 2018, the World Health Organization (WHO) convened experts to address this pressing issue. What makes Lassa virus so challenging is its extensive diversity; the genetic variation among Lassa virus isolates from West African patients surpasses that of Ebola virus during the 2013-2016 epidemic.
This genetic variability creates a significant hurdle for vaccine development, demanding that vaccines offer broad protection against a wide range of Lassa virus strains. Researchers are actively exploring how to stimulate the immune system to recognize and defend against these diverse viral threats.
This article examines the current understanding of the immune response to Lassa virus infection and discusses strategies for designing broadly protective vaccines. We'll explore approaches used in influenza vaccine development and recent advances in AIDS research, considering their potential application in creating effective medical countermeasures against Lassa virus disease.
Lassa Fever’s Regional Burden
Lassa fever causes an estimated 300,000 cases annually, while another source estimates about half a million cases each year in West Africa. Both sources report about 5,000 deaths, and the vaccine tracker identifies Nigeria, Sierra Leone, Guinea, and Liberia as the countries primarily affected. No licensed vaccine exists, and West African health ministers pledged in 2025 to advance vaccine development and readiness.
Vaccine Strategies and Barriers
No vaccine against Lassa fever is currently licensed for human use. Live-attenuated viruses and recombinant viral vectors are considered attractive vaccine-development approaches, and observations suggest that surviving a single Lassa virus infection may provide long-term protection against fatal disease. Progress is hampered by the virus’s genetic heterogeneity, the lack of established immune correlates of protection, and the logistical difficulty of conducting large efficacy trials in resource-limited settings with sporadic outbreaks. Vaccinating rodents is also proposed as an innovative One Health strategy for reducing disease incidence in hyperendemic areas.
First Described in 1969
Lassa fever was first described in Nigeria in 1969. A 2019 historical review reported that 59 million people were at risk in West Africa and cited estimates of 3 million cases and 67,000 deaths annually. The review also noted that the World Health Organization’s Blueprint for Action prioritized vaccine development and that CEPI was funding vaccine research.
Why is Lassa Virus So Hard to Target?
Lassa virus (LASV) is a zoonotic pathogen that's endemic to West Africa, causing annual outbreaks primarily during the dry season in rural areas. Unlike the concentrated outbreaks of Ebola, Lassa outbreaks stem from varied exposures to the rodent reservoir, leading to its high genetic variation. This means any effective vaccine needs to cover a broader range of viral strains than, for example, an Ebola vaccine.
- Vaccine Cross-Protection: Reflects the genetic diversity a vaccine can handle.
- Narrow Protection: Only effective against closely-related Lassa lineages (5-7% nucleotide sequence difference).
- Broad Protection: Could defend against all Lassa lineages (up to 27% nucleotide difference).
- Ideal Scenario: Protection against other arenavirus species (30-50% nucleotide difference, e.g., between LASV and LCMV).
Candidate Platforms in Development
A mouse study reported protection from lethal intracerebral virus challenge after a single dose of modified vaccinia Ankara expressing Lassa virus-like particles. In that approach, expression of two viral proteins produced non-infectious particles bearing natively folded glycoproteins, which the authors said could trigger a broader cross-protective response than vaccines expressing a single viral antigen. A 2024 review describes several candidate vaccines entering clinical trials with promising early results, while emphasizing that development is ongoing.
Immune Response Complicates Protection
The relationship between Lassa virus infection and disease severity is not explained by viral burden alone: one review reports a strong correlation between viremia and outcome, but says tissue damage does not appear to result directly from viral-cell lysis. Instead, that source points to the initial host immune response as a factor in disease damage. Separately, a 2025 report stated that no Lassa fever vaccine was then available and described a replication-competent recombinant vesicular stomatitis virus vaccine in a safety and immunogenicity study.
Genetic Diversity Challenges Coverage
Lassa virus has high genetic diversity across West Africa, and its glycoprotein reflects variation among viral lineages. Most vaccine candidates discussed in the 2020 study used the Lineage IV Josiah strain glycoprotein as the immunogen and tested protection against homologous Lineage IV virus. The study identifies this focus alongside wider lineage variation as a challenge for vaccine breadth. Another review identifies genetic diversity as the greatest challenge for vaccine development and describes the reassortant ML29 candidate.
The Future of Lassa Fever Protection
While current research offers hope, there's a need for more comprehensive comparisons of existing vaccine candidates. Factors like stability, production capacity, and the breadth of protection in primates remain unknown. Once these are established, efforts should focus on two key areas: developing affordable vaccines for emergency use in endemic regions and creating more specialized vaccines for vulnerable populations like pregnant women.
Progress with Coverage Questions
A 2025 review notes that most Lassa vaccines in clinical development have focused on a single lineage, typically Lineage IV, despite the virus’s known genetic diversity across affected regions. The authors say this concentration may have implications for cross-protection and long-term efficacy. A separate scoping review concludes that vaccine development remains in its early stages, while describing progress toward a safe and effective vaccine as encouraging.
Research and Equitable Access
A 2023 scoping review compares Lassa vaccine candidates and trials with the World Health Organization’s target product profile and characterizes development as early-stage but encouraging. CEPI’s 2025 agenda included developing a policy research agenda, reviewing plans to enable equitable access to future vaccine doses, and continuing support for Lassa fever research and development. These priorities link candidate progress with planning for eventual vaccine access.
Regional Needs for a Future Vaccine
Lassa fever is a zoonotic viral hemorrhagic disease endemic to several West African countries. A 2024 article estimates 300,000–500,000 cases annually across all ages and reports case fatality rates of 10–20%. The article describes a Lassa fever vaccine as a public health priority, with several candidates entering clinical trials, and examines regional experts’ perspectives on critical vaccine properties and ideal use.
Further improvements in vaccine design should aim to boost immunity to conformational antigens—those that maintain stable functionality during virus evolution. Also, targeting epitopes known to tightly bind to HLA (human leukocyte antigen) and cross-restrict with conformational antigens could yield more broadly effective immune responses.
By combining these advanced vaccine strategies with effective therapeutic drugs, we can significantly improve our ability to combat Lassa fever and protect vulnerable communities.